Nicole L. McNeil

Ms. McNeil's experience includes representing:

• Issuers and underwriters in connection with capital markets transactions predominately in the life sciences and healthcare industries, including initial public offerings and equity follow-on offerings
• Ongoing public company clients with respect to general corporate governance matters, SEC compliance and securities law issues, disclosure and reporting obligations, including preparation of SEC disclosure documents, and listed company obligations
• Start-up companies in venture financing transactions, as well as matters related to general corporate governance, securities law issues, employment, and intellectual property

Ms. McNeil's representative transactions as company counsel include advising:

• Evelo Biosciences in its US$85 million initial public offering of its common stock 
• Homology Medicines in its US$165 million initial public offering of its common stock and follow-on offerings
• Press Ganey in its US$255 million initial public offering of its common stock
• Selecta Biosciences in its US$70 million initial public offering of its common stock and follow-on offerings
• BIND Therapeutics in its US$70 million initial public offering of its common stock and follow-on offerings

Ms. McNeil's representative transactions as underwriters' counsel include advising:

• Jefferies, Leerink Partners, and BMO Capital Markets in scPharmaceuticals’ US$102 million initial public offering
• Bank of America in Aileron Therapeutics’ US$56 million initial public offering
• Goldman Sachs and Morgan Stanley in US$144 million and US$230 million follow-on offerings by Blueprint Medicines
• UBS and Morgan Stanley in follow-on offerings by Akebia Therapeutics
• BMO and Stifel in follow-on offerings by Tetraphase Pharmaceuticals